Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumors.

Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, Patel YT, Onar-Thomas A, Campagne O, Ward DA, Broniscer A, Robinson G, Gajjar A, Stewart CF.

Br J Clin Pharmacol. 2019 Oct 28. doi: 10.1111/bcp.14160. [Epub ahead of print]

PMID:
31657864
2.

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.

Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC.

Int J Cancer. 2017 Oct 1;141(7):1469-1477. doi: 10.1002/ijc.30841. Epub 2017 Jul 3.

3.

Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients.

Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF.

Pediatr Nephrol. 2017 Sep;32(9):1575-1584. doi: 10.1007/s00467-017-3693-5. Epub 2017 Jun 2.

4.

Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.

Patel YT, Daryani VM, Patel P, Zhou D, Fangusaro J, Carlile DJ, Martin PD, Aarons L, Stewart CF.

CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):305-314. doi: 10.1002/psp4.12175. Epub 2017 Mar 22. Erratum in: CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10 ):719.

5.

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R.

J Neurooncol. 2016 Sep;129(3):443-451. doi: 10.1007/s11060-016-2189-7. Epub 2016 Jun 27.

6.

Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A.

Cancer Med. 2016 Jul;5(7):1416-24. doi: 10.1002/cam4.713. Epub 2016 Apr 25.

7.

Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.

Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajjar A, Gilbertson RJ, Wright KD, Stewart CF.

CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):211-221. doi: 10.1002/psp4.12075. Epub 2016 Apr 14.

8.

Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF.

Drug Metab Dispos. 2016 Jul;44(7):1116-22. doi: 10.1124/dmd.115.068676. Epub 2016 Apr 6.

9.

Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.

Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A.

Pediatr Blood Cancer. 2016 Jul;63(7):1207-13. doi: 10.1002/pbc.25983. Epub 2016 Apr 1.

10.

Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate.

Roberts MS, Selvo NS, Roberts JK, Daryani VM, Owens TS, Harstead KE, Gajjar A, Stewart CF.

J Liq Chromatogr Relat Technol. 2016;39(16):745-751. doi: 10.1080/10826076.2016.1243558. Epub 2016 Oct 10.

11.

Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma.

Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA, Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, Krull KR.

JAMA Oncol. 2016 Feb;2(2):201-8. doi: 10.1001/jamaoncol.2015.4398.

12.

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A.

Neuro Oncol. 2015 Dec;17(12):1620-7. doi: 10.1093/neuonc/nov181. Epub 2015 Nov 4.

13.

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.

Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, Madewell JE, Navid F, Daw NC, Reddick WE.

Br J Cancer. 2015 Nov 3;113(9):1282-8. doi: 10.1038/bjc.2015.351. Epub 2015 Oct 13.

14.

Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF.

Clin Pharmacokinet. 2016 Mar;55(3):297-311. doi: 10.1007/s40262-015-0319-6. Review.

15.

Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ.

Childs Nerv Syst. 2015 Aug;31(8):1283-9. doi: 10.1007/s00381-015-2725-3. Epub 2015 May 1.

Supplemental Content

Loading ...
Support Center